{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:22:55Z","timestamp":1793726575571,"version":"4.6.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-10875-5","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T18:25:55Z","timestamp":1753986355000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Retrospective study of onychomycosis patients treated with ciclopirox 8% HPCH and oral antifungals applying artificial intelligence to electronic health records"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3632-9636","authenticated-orcid":false,"given":"Gast\u00f3n","family":"Roustan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8816-1989","authenticated-orcid":false,"given":"Jos\u00e9 Luis","family":"L\u00f3pez Est\u00e9baranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4807-3551","authenticated-orcid":false,"given":"Pablo","family":"De La Cueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Savana Research Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Cabal-Hierro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Casadevall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Fanjul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Mar\u00edn-Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Mat\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Menke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Polo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Posso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Salcedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Salvador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miren","family":"Taberna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8339-2406","authenticated-orcid":false,"given":"Francesca","family":"Pajuelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Luisa","family":"Tamarit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6739-0996","authenticated-orcid":false,"given":"Aida","family":"Valmaseda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2435-2129","authenticated-orcid":false,"given":"Jordi","family":"Galv\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"10875_CR1","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1111\/jdv.13677","volume":"30","author":"AK Gupta","year":"2016","unstructured":"Gupta, A. K. et al. The prevalence of unsuspected onychomycosis and its causative organisms in a multicentre Canadian sample of 30 000 patients visiting physicians\u2019 offices. J. Eur. Acad. Dermatol. Venereol. 30, 1567\u20131572. https:\/\/doi.org\/10.1111\/jdv.13677 (2016).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10875_CR2","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1111\/jdv.12323","volume":"28","author":"B Sigurgeirsson","year":"2014","unstructured":"Sigurgeirsson, B. & Baran, R. The prevalence of onychomycosis in the global population: a literature study. J. Eur. Acad. Dermatol. Venereol. 28, 1480\u20131491. https:\/\/doi.org\/10.1111\/jdv.12323 (2014).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10875_CR3","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1067\/mjd.2000.104794","volume":"43","author":"AK Gupta","year":"2000","unstructured":"Gupta, A. K. et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians\u2019 offices: a multicenter Canadian survey of 15,000 patients. J. Am. Acad. Dermatol. 43, 244\u2013248. https:\/\/doi.org\/10.1067\/mjd.2000.104794 (2000).","journal-title":"J. Am. Acad. Dermatol."},{"key":"10875_CR4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.1365-2710.2009.01107.x","volume":"35","author":"J Thomas","year":"2010","unstructured":"Thomas, J. et al. Toenail onychomycosis: an important global disease burden. J. Clin. Pharm. Ther. 35, 497\u2013519. https:\/\/doi.org\/10.1111\/j.1365-2710.2009.01107.x (2010).","journal-title":"J. Clin. Pharm. Ther."},{"key":"10875_CR5","doi-asserted-by":"publisher","unstructured":"Navarro-Perez, D. et al. Prevalence and risk factors predicting onychomycosis in patients with and without diabetes mellitus in spain: A Cross-Sectional study. J. Fungi (Basel). 10 https:\/\/doi.org\/10.3390\/jof10110790 (2024).","DOI":"10.3390\/jof10110790"},{"key":"10875_CR6","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/ijd.12122","volume":"52","author":"A Chacon","year":"2013","unstructured":"Chacon, A., Franca, K., Fernandez, A. & Nouri, K. Psychosocial impact of onychomycosis: a review. Int. J. Dermatol. 52, 1300\u20131307. https:\/\/doi.org\/10.1111\/ijd.12122 (2013).","journal-title":"Int. J. Dermatol."},{"key":"10875_CR7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2165\/00019053-199813020-00007","volume":"13","author":"AK Gupta","year":"1998","unstructured":"Gupta, A. K. Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. A US analysis. Pharmacoeconomics 13, 243\u2013256. https:\/\/doi.org\/10.2165\/00019053-199813020-00007 (1998).","journal-title":"Pharmacoeconomics"},{"key":"10875_CR8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1159\/000485632","volume":"4","author":"AK Gupta","year":"2018","unstructured":"Gupta, A. K. & Mays, R. R. The impact of onychomycosis on quality of life: A systematic review of the available literature. Skin. Appendage Disord. 4, 208\u2013216. https:\/\/doi.org\/10.1159\/000485632 (2018).","journal-title":"Skin. Appendage Disord"},{"key":"10875_CR9","unstructured":"Bodman, M. A., Syed, H. A. & Krishnamurthy, K. in StatPearls (2024)."},{"key":"10875_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.2174\/1872213X13666191026090713","volume":"14","author":"AKC Leung","year":"2020","unstructured":"Leung, A. K. C. et al. Onychomycosis: an updated review. Recent. Pat. Inflamm. Allergy Drug Discov. 14, 32\u201345. https:\/\/doi.org\/10.2174\/1872213X13666191026090713 (2020).","journal-title":"Recent. Pat. Inflamm. Allergy Drug Discov"},{"key":"10875_CR11","doi-asserted-by":"publisher","unstructured":"Maskan Bermudez, N., Rodriguez-Tamez, G., Perez, S., Tosti, A. & Onychomycosis Old and new. J. Fungi (Basel). 9 https:\/\/doi.org\/10.3390\/jof9050559 (2023).","DOI":"10.3390\/jof9050559"},{"key":"10875_CR12","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.2147\/CCID.S362635","volume":"15","author":"JM Falotico","year":"2022","unstructured":"Falotico, J. M. & Lipner, S. R. Updated perspectives on the diagnosis and management of onychomycosis. Clin. Cosmet. Investig Dermatol. 15, 1933\u20131957. https:\/\/doi.org\/10.2147\/CCID.S362635 (2022).","journal-title":"Clin. Cosmet. Investig Dermatol."},{"key":"10875_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jaad.2019.12.019","volume":"83","author":"S Geizhals","year":"2020","unstructured":"Geizhals, S., Cooley, V. & Lipner, S. R. Diagnostic testing for onychomycosis: A retrospective study over 17 years. J. Am. Acad. Dermatol. 83, 239\u2013241. https:\/\/doi.org\/10.1016\/j.jaad.2019.12.019 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"10875_CR14","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1610-0387.2012.07964.x","volume":"10","author":"Y Graser","year":"2012","unstructured":"Graser, Y., Czaika, V., Ohst, T. & Diagnostic PCR of dermatophytes\u2013an overview. J. Dtsch. Dermatol. Ges. 10, 721\u2013726. https:\/\/doi.org\/10.1111\/j.1610-0387.2012.07964.x (2012).","journal-title":"J. Dtsch. Dermatol. Ges"},{"key":"10875_CR15","doi-asserted-by":"publisher","unstructured":"Gupta, A. K., Hall, D. C., Cooper, E. A. & Ghannoum, M. A. Diagnosing Onychomycosis: What\u2019s New? J. Fungi (Basel). 8 https:\/\/doi.org\/10.3390\/jof8050464 (2022).","DOI":"10.3390\/jof8050464"},{"key":"10875_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1468-3083.2004.00988.x","volume":"19","author":"R Baran","year":"2005","unstructured":"Baran, R. & Kaoukhov, A. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J. Eur. Acad. Dermatol. Venereol. 19, 21\u201329. https:\/\/doi.org\/10.1111\/j.1468-3083.2004.00988.x (2005).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10875_CR17","doi-asserted-by":"publisher","unstructured":"Feng, X., Xiong, X. & Ran, Y. Efficacy and tolerability of Amorolfine 5% nail lacquer in combination with systemic antifungal agents for onychomycosis: A meta-analysis and systematic review. Dermatol. Ther. 30 https:\/\/doi.org\/10.1111\/dth.12457 (2017).","DOI":"10.1111\/dth.12457"},{"key":"10875_CR18","unstructured":"Almirall. in almirall.com. (ed. Almirall) 60 (2020)."},{"key":"10875_CR19","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1111\/jdv.19217","volume":"37","author":"AK Gupta","year":"2023","unstructured":"Gupta, A. K., Talukder, M., Carviel, J. L., Cooper, E. A. & Piguet, V. Combatting antifungal resistance: paradigm shift in the diagnosis and management of onychomycosis and dermatomycosis. J. Eur. Acad. Dermatol. Venereol. 37, 1706\u20131717. https:\/\/doi.org\/10.1111\/jdv.19217 (2023).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10875_CR20","doi-asserted-by":"publisher","first-page":"e13683","DOI":"10.1111\/myc.13683","volume":"67","author":"AK Gupta","year":"2024","unstructured":"Gupta, A. K. et al. Treatment of onychomycosis in an era of antifungal resistance: role for antifungal stewardship and topical antifungal agents. Mycoses 67, e13683. https:\/\/doi.org\/10.1111\/myc.13683 (2024).","journal-title":"Mycoses"},{"key":"10875_CR21","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2147\/PPA.S450215","volume":"18","author":"AT Mickle","year":"2024","unstructured":"Mickle, A. T. et al. Toenail onychomycosis with or without diabetes in canada: patient treatment preferences and health state utilities. Patient Prefer Adherence. 18, 475\u2013486. https:\/\/doi.org\/10.2147\/PPA.S450215 (2024).","journal-title":"Patient Prefer Adherence"},{"key":"10875_CR22","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.jaad.2018.05.1260","volume":"80","author":"SR Lipner","year":"2019","unstructured":"Lipner, S. R., Scher, R. K. & Onychomycosis Treatment and prevention of recurrence. J. Am. Acad. Dermatol. 80, 853\u2013867. https:\/\/doi.org\/10.1016\/j.jaad.2018.05.1260 (2019).","journal-title":"J. Am. Acad. Dermatol."},{"key":"10875_CR23","doi-asserted-by":"publisher","first-page":"100949","DOI":"10.1016\/j.mycmed.2020.100949","volume":"30","author":"R Aggarwal","year":"2020","unstructured":"Aggarwal, R., Targhotra, M., Kumar, B., Sahoo, P. K. & Chauhan, M. K. Treatment and management strategies of onychomycosis. J. Mycol. Med. 30, 100949. https:\/\/doi.org\/10.1016\/j.mycmed.2020.100949 (2020).","journal-title":"J. Mycol. Med."},{"key":"10875_CR24","first-page":"24","volume":"17","author":"F Yousefian","year":"2024","unstructured":"Yousefian, F., Smythe, C., Han, H., Elewski, B. E. & Nestor, M. Treatment options for onychomycosis: efficacy, side effects, adherence, financial considerations, and ethics. J. Clin. Aesthet. Dermatol. 17, 24\u201333 (2024).","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"10875_CR25","doi-asserted-by":"publisher","unstructured":"Alves, R. O. et al. Antimicrobial photodynamic therapy in onychomycosis management: A systematic review of clinical trials. Photodiagnosis Photodyn Ther. 104640 https:\/\/doi.org\/10.1016\/j.pdpdt.2025.104640 (2025).","DOI":"10.1016\/j.pdpdt.2025.104640"},{"key":"10875_CR26","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s13555-020-00420-9","volume":"10","author":"BM Piraccini","year":"2020","unstructured":"Piraccini, B. M., Iorizzo, M., Lencastre, A., Nenoff, P. & Rigopoulos, D. Ciclopirox hydroxypropyl Chitosan (HPCH) nail lacquer: A review of its use in onychomycosis. Dermatol. Ther. (Heidelb). 10, 917\u2013929. https:\/\/doi.org\/10.1007\/s13555-020-00420-9 (2020).","journal-title":"Dermatol. Ther. (Heidelb)"},{"key":"10875_CR27","doi-asserted-by":"publisher","unstructured":"Falotico, J. M., Lapides, R. & Lipner, S. R. Combination therapy should be reserved as Second-Line treatment of onychomycosis: A systematic review of onychomycosis clinical trials. J. Fungi (Basel). 8 https:\/\/doi.org\/10.3390\/jof8030279 (2022).","DOI":"10.3390\/jof8030279"},{"key":"10875_CR28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.9781\/ijimai.2017.03.001","volume":"4","author":"I Hern\u00e1ndez Medrano","year":"2018","unstructured":"Hern\u00e1ndez Medrano, I. et al. Savana: Re-using electronic health records with artificial intelligence. IJIMAI J. 4, 5. https:\/\/doi.org\/10.9781\/ijimai.2017.03.001 (2018).","journal-title":"IJIMAI J."},{"key":"10875_CR29","first-page":"23","volume":"57","author":"L Espinosa-Anke","year":"2016","unstructured":"Espinosa-Anke, L. et al. Savana: A global information extraction and terminology expansion framework in the medical domain. Proces Del. Leng Nat. 57, 23\u201330 (2016). http:\/\/journal.sepln.org\/sepln\/ojs\/ojs\/index.php\/pln\/article\/view\/5333","journal-title":"Proces Del. Leng Nat."},{"key":"10875_CR30","doi-asserted-by":"publisher","unstructured":"Brescini, L., Fioriti, S., Morroni, G. & Barchiesi, F. Antifungal combinations in dermatophytes. J. Fungi (Basel). 7 https:\/\/doi.org\/10.3390\/jof7090727 (2021).","DOI":"10.3390\/jof7090727"},{"key":"10875_CR31","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/j.1468-3083.2009.03164.x","volume":"23","author":"R Baran","year":"2009","unstructured":"Baran, R. et al. An innovative water-soluble biopolymer improves efficacy of Ciclopirox nail lacquer in the management of onychomycosis. J. Eur. Acad. Dermatol. Venereol. 23, 773\u2013781. https:\/\/doi.org\/10.1111\/j.1468-3083.2009.03164.x (2009).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10875_CR32","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/09546630500420183","volume":"16","author":"S Avner","year":"2005","unstructured":"Avner, S., Nir, N. & Henri, T. Combination of oral terbinafine and topical Ciclopirox compared to oral terbinafine for the treatment of onychomycosis. J. Dermatolog Treat. 16, 327\u2013330. https:\/\/doi.org\/10.1080\/09546630500420183 (2005).","journal-title":"J. Dermatolog Treat."},{"key":"10875_CR33","first-page":"481","volume":"4","author":"AK Gupta","year":"2005","unstructured":"Gupta, A. K. & Study, O. C. T. Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study. J. Drugs Dermatol. 4, 481\u2013485 (2005).","journal-title":"J. Drugs Dermatol."},{"key":"10875_CR34","doi-asserted-by":"publisher","first-page":"393","DOI":"10.4103\/0378-6323.37056","volume":"73","author":"A Jaiswal","year":"2007","unstructured":"Jaiswal, A., Sharma, R. P. & Garg, A. P. An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical Ciclopirox olamine 8% or topical Amorolfine hydrochloride 5% in the treatment of onychomycosis. Indian J. Dermatol. Venereol. Leprol. 73, 393\u2013396. https:\/\/doi.org\/10.4103\/0378-6323.37056 (2007).","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"10875_CR35","doi-asserted-by":"publisher","unstructured":"Albucker, S. J., Falotico, J. M., Choo, Z. N., Matushansky, J. T. & Lipner, S. R. Risk factors and treatment trends for onychomycosis: A Case-Control study of onychomycosis patients in the all of Us research program. J. Fungi (Basel). 9 https:\/\/doi.org\/10.3390\/jof9070712 (2023).","DOI":"10.3390\/jof9070712"},{"key":"10875_CR36","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00403-020-02044-7","volume":"312","author":"Y Wang","year":"2020","unstructured":"Wang, Y. & Lipner, S. R. Retrospective analysis of adverse events with topical onychomycosis medications reported to the united States food and drug administration. Arch. Dermatol. Res. 312, 581\u2013586. https:\/\/doi.org\/10.1007\/s00403-020-02044-7 (2020).","journal-title":"Arch. Dermatol. Res."},{"key":"10875_CR37","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1080\/09546634.2019.1708242","volume":"32","author":"Y Wang","year":"2021","unstructured":"Wang, Y. & Lipner, S. R. Retrospective analysis of adverse events with systemic onychomycosis medications reported to the united States food and drug administration. J. Dermatolog Treat. 32, 783\u2013787. https:\/\/doi.org\/10.1080\/09546634.2019.1708242 (2021).","journal-title":"J. Dermatolog Treat."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10875-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10875-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10875-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T04:09:00Z","timestamp":1754366940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10875-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10875"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-10875-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"30 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Approval by the Ethics Committee of the participating hospitals was obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}}],"article-number":"27978"}}